$CRDF
Cardiff Oncology, Inc. Stock $crdf

$crdf Overview Financials Valuation SEC Filings Company Website

2017 Q3 Form 10-Q Financial Statement

#000162828017011252 Filed on November 09, 2017

Income Statement

Concept	2017 Q3	2016 Q3
Revenue	$123.3K	$89.00K
YoY Change	38.57%	53.45%
Cost Of Revenue	$473.2K	$424.6K
YoY Change	11.46%	144.65%
Gross Profit	-$349.9K	-$335.6K
YoY Change	4.27%	190.43%
Gross Profit Margin	-283.69%	-377.03%
Selling, General & Admin	$4.080M	$5.652M
YoY Change	-27.82%	50.84%
% of Gross Profit
Research & Development	$1.415M	$3.937M
YoY Change	-64.07%	54.62%
% of Gross Profit
Depreciation & Amortization	$310.0K	$200.0K
YoY Change	55.0%	100.0%
% of Gross Profit
Operating Expenses	$5.921M	$10.01M
YoY Change	-40.87%	54.83%
Operating Profit	-$5.798M	-$9.924M
YoY Change	-41.58%	54.84%
Interest Expense	$37.12K	-$270.0K
YoY Change	-113.75%	-176.55%
% of Operating Profit
Other Income/Expense, Net	-$6.541K	$0.00
YoY Change		-100.0%
Pretax Income	-$4.290M	-$10.19M
YoY Change	-57.9%	271.9%
Income Tax
% Of Pretax Income
Net Earnings	-$4.292M	-$10.19M
YoY Change	-57.89%	272.51%
Net Earnings / Revenue	-3480.09%	-11450.87%
Basic Earnings Per Share	-$1.41	-$0.34
Diluted Earnings Per Share	-$1.41	-$0.34
COMMON SHARES
Basic Shares Outstanding	3.039M shares	30.34M shares
Diluted Shares Outstanding	3.039M shares	30.34M shares

Balance Sheet

Concept	2017 Q3	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.400M	$46.90M
YoY Change	-84.22%	-36.71%
Cash & Equivalents	$7.434M	$22.57M
Short-Term Investments	$0.00	$24.40M
Other Short-Term Assets	$900.0K	$900.0K
YoY Change	0.0%	50.0%
Inventory
Prepaid Expenses
Receivables	$178.1K	$85.15K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$8.552M	$47.98M
YoY Change	-82.18%	-35.87%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.127M	$4.655M
YoY Change	-32.82%	152.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$539.3K	$371.2K
YoY Change	45.27%	2.29%
Total Long-Term Assets	$3.666M	$5.026M
YoY Change	-27.06%	127.93%
TOTAL ASSETS
Total Short-Term Assets	$8.552M	$47.98M
Total Long-Term Assets	$3.666M	$5.026M
Total Assets	$12.22M	$53.00M
YoY Change	-76.95%	-31.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$675.5K	$925.2K
YoY Change	-26.99%	-15.9%
Accrued Expenses	$2.620M	$4.559M
YoY Change	-42.52%	114.63%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.500M	$800.0K
YoY Change	87.5%	-78.38%
Total Short-Term Liabilities	$5.082M	$6.565M
YoY Change	-22.59%	-5.81%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$15.60M
YoY Change	-100.0%	35.65%
Other Long-Term Liabilities	$3.200M	$4.100M
YoY Change	-21.95%	10.81%
Total Long-Term Liabilities	$3.200M	$19.70M
YoY Change	-83.76%	29.61%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.082M	$6.565M
Total Long-Term Liabilities	$3.200M	$19.70M
Total Liabilities	$8.273M	$26.23M
YoY Change	-68.46%	18.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$170.5M	-$139.6M
YoY Change	22.15%	37.5%
Common Stock	$3.811K	$3.060K
YoY Change	24.54%	2.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.945M	$26.77M
YoY Change
Total Liabilities & Shareholders Equity	$12.22M	$53.00M
YoY Change	-76.95%	-31.18%

Cashflow Statement

Concept	2017 Q3	2016 Q3
OPERATING ACTIVITIES
Net Income	-$4.292M	-$10.19M
YoY Change	-57.89%	272.51%
Depreciation, Depletion And Amortization	$310.0K	$200.0K
YoY Change	55.0%	100.0%
Cash From Operating Activities	-$6.590M	-$7.050M
YoY Change	-6.52%	37.43%
INVESTING ACTIVITIES
Capital Expenditures	-$120.0K	-$130.0K
YoY Change	-7.69%	-77.19%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$3.500M
YoY Change	-100.0%
Cash From Investing Activities	-$110.0K	$3.370M
YoY Change	-103.26%	-691.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	6.370M	3.660M
YoY Change	74.04%	-90.51%
NET CHANGE
Cash From Operating Activities	-6.590M	-7.050M
Cash From Investing Activities	-110.0K	3.370M
Cash From Financing Activities	6.370M	3.660M
Net Change In Cash	-330.0K	-20.00K
YoY Change	1550.0%	-100.06%
FREE CASH FLOW
Cash From Operating Activities	-$6.590M	-$7.050M
Capital Expenditures	-$120.0K	-$130.0K
Free Cash Flow	-$6.470M	-$6.920M
YoY Change	-6.5%	51.75%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	trov	Diagnostic Service Revenue DiagnosticServiceRevenue	142482	USD
	trov	Increase In Derivative Liability Due To Issuance Of Warrants IncreaseInDerivativeLiabilityDueToIssuanceOfWarrants	3215519	USD
	trov	Leaseholdimprovementspaidforbylessor Leaseholdimprovementspaidforbylessor	1860000	USD
	trov	Leaseholdimprovementspaidforbylessor Leaseholdimprovementspaidforbylessor	0	USD
	trov	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	18180	USD
	trov	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	18180	USD
	trov	Stock Issued During Period Restricted Stock Units StockIssuedDuringPeriodRestrictedStockUnits	369487	shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001213037
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	38106460	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	Trovagene, Inc.
CY2016Q3	trov	Adjustment For Change In Unrealized Gain Loss On Derivatives AdjustmentForChangeInUnrealizedGainLossOnDerivatives	0	USD
	trov	Adjustment For Change In Unrealized Gain Loss On Derivatives AdjustmentForChangeInUnrealizedGainLossOnDerivatives	-533750	USD
CY2017Q3	trov	Adjustment For Change In Unrealized Gain Loss On Derivatives AdjustmentForChangeInUnrealizedGainLossOnDerivatives	0	USD
	trov	Adjustment For Change In Unrealized Gain Loss On Derivatives AdjustmentForChangeInUnrealizedGainLossOnDerivatives	0	USD
	trov	Amortized Portion Of Final Fee Upon Repayment AmortizedPortionOfFinalFeeUponRepayment	266423	USD
	trov	Amortized Portion Of Final Fee Upon Repayment AmortizedPortionOfFinalFeeUponRepayment	293614	USD
	trov	Class Of Warrant Or Right Number Expired ClassOfWarrantOrRightNumberExpired	1177024	shares
	trov	Class Of Warrant Or Right Number Granted ClassOfWarrantOrRightNumberGranted	4643626	shares
CY2016	trov	Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights	P1Y7M6D
	trov	Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights	P3Y3M2D
CY2016Q4	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	3.83
CY2017Q3	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	2.38
	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Expired ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired	5.32
	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Granted ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted	1.41
CY2016Q3	trov	Comprehensive Income Loss Availableto Common Stockholders Basic ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic	-10205410	USD
CY2016Q3	trov	Diagnostic Service Revenue DiagnosticServiceRevenue	37978	USD
	trov	Comprehensive Income Loss Availableto Common Stockholders Basic ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic	-30678990	USD
CY2017Q3	trov	Diagnostic Service Revenue DiagnosticServiceRevenue	58119	USD
	trov	Diagnostic Service Revenue DiagnosticServiceRevenue	69558	USD
CY2015Q4	trov	Operating Lease Monthly Rent OperatingLeaseMonthlyRent	3100	USD
	trov	Operating Lease Monthly Rent OperatingLeaseMonthlyRent	68000	USD
CY2017Q3	trov	Comprehensive Income Loss Availableto Common Stockholders Basic ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic	-4299570	USD
	trov	Comprehensive Income Loss Availableto Common Stockholders Basic ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic	-22359915	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1130536	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	167890984	USD
CY2017Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	174426891	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1829371	USD
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	675499	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	100460	USD
CY2017Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	178127	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-61719	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-9230	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4021365	USD
CY2017Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2620250	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1761985	USD
CY2017Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2528617	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-10773	USD
CY2017Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-15194	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5942392	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1421180	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3117364	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	105710	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	113780	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11053250	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14569961	shares
CY2017Q3	us-gaap	Area Of Land AreaOfLand	26100	sqft
CY2015Q4	us-gaap	Area Of Land AreaOfLand	2300	sqft
CY2016Q4	us-gaap	Assets Assets	43950411	USD
CY2017Q3	us-gaap	Assets Assets	12217903	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	38950192	USD
CY2017Q3	us-gaap	Assets Current AssetsCurrent	8551625	USD
CY2016Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	374	USD
CY2016Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	9439	USD
CY2016Q4	us-gaap	Available For Sale Securities Short Term Investments Amortized Cost AvailableForSaleSecuritiesShortTermInvestmentsAmortizedCost	23987087	USD
	us-gaap	Availableforsale Securities Gross Realized Gain Loss Excluding Other Than Temporary Impairments AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments	0	USD
	us-gaap	Availableforsale Securities Gross Realized Gain Loss Excluding Other Than Temporary Impairments AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments	-6400	USD
	us-gaap	Availableforsale Securities Gross Realized Gain Loss Excluding Other Than Temporary Impairments AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments	-6400	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	67493047	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22569107	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13915094	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7434298	USD
CY2016Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5505901	shares
CY2017Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	8972503	shares
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	-10122	USD
CY2016Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	285246	USD
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30696791	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38105251	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30696791	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38105251	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	3070	USD
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	3811	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10199350	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30660810	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4293510	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22341735	USD
CY2016Q3	us-gaap	Cost Of Revenue CostOfRevenue	424559	USD
	us-gaap	Cost Of Revenue CostOfRevenue	1143293	USD
CY2017Q3	us-gaap	Cost Of Revenue CostOfRevenue	473202	USD
	us-gaap	Cost Of Revenue CostOfRevenue	1427831	USD
CY2017Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	298213	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1373717	USD
CY2017Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1153316	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	693485	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	956995	USD
CY2016Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	834940	USD
CY2017Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2037712	USD
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.02
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.68
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.04
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.68
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-1544	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-8837	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-28199	USD
CY2016Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2017Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1655825	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2710782	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9183761	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3659587	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9915359	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	4560	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	800	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2490137	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1908796	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-13584	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	77667	USD
	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	90330	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	133378	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	207435	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2761	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	157051	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-18230	USD
CY2016Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	117731	shares
CY2017Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2016Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-354993	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-967522	USD
CY2017Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-16473	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-877741	USD
	us-gaap	Interest Paid InterestPaid	806228	USD
	us-gaap	Interest Paid InterestPaid	650331	USD
CY2016Q4	us-gaap	Liabilities Liabilities	24182272	USD
CY2017Q3	us-gaap	Liabilities Liabilities	8273031	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	43950411	USD
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12217903	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7797256	USD
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5082003	USD
CY2017Q3	us-gaap	Litigation Reserve LitigationReserve	2100000	USD
CY2016Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	14176359	USD
CY2017Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	0	USD
CY2016Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	2360109	USD
CY2017Q3	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	1488041	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-44923940	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-6480796	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2361994	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-10447842	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-25249392	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	23925535	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-22034998	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-19949652	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-10191272	USD
	us-gaap	Net Income Loss NetIncomeLoss	-30656068	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-4291966	USD
	us-gaap	Net Income Loss NetIncomeLoss	-22337314	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10197332	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-30674248	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4298026	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22355494	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-10197332	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-31207998	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4298026	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-22355494	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	10013601	USD
	us-gaap	Operating Expenses OperatingExpenses	30676380	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	5920950	USD
	us-gaap	Operating Expenses OperatingExpenses	22131898	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9924487	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-30363380	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5797621	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21811520	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1173304	USD
CY2017Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	539309	USD
CY2016Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-81	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1877	USD
CY2017Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1544	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-13486	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-8078	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-4742	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1544	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-4421	USD
CY2016Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-7997	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2865	USD
CY2017Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	9065	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6541	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4975	USD
CY2016Q3	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	3900	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	35573	USD
CY2017Q3	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	6431	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	8481	USD
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	0	USD
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	1613067	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	24451611	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	8804604	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	797781	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	136251	USD
CY2016Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6060	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	18180	USD
CY2017Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6060	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	18180	USD
CY2016Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	606000	USD
CY2017Q3	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	606000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2017Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	60600	shares
CY2017Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	60600	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	60	USD
CY2017Q3	us-gaap	Preferred Stock Value PreferredStockValue	60	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	956616	USD
CY2017Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	939200	USD
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	7805086	USD
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2293857	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6634803	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	110000	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	792251	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	16431837	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	0	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	16434553	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	366966	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5588900	USD
CY2017Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5655586	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3826915	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3126969	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	8896166	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	15000000	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	0	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	469578	USD
CY2016Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3937398	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	11221876	USD
CY2017Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1414706	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	6676251	USD
CY2017Q3	us-gaap	Restructuring And Related Cost Expected Cost1 RestructuringAndRelatedCostExpectedCost1	2000000	USD
CY2016Q3	us-gaap	Restructuring Charges RestructuringCharges	0	USD
	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2017Q3	us-gaap	Restructuring Charges RestructuringCharges	-46472	USD
	us-gaap	Restructuring Charges RestructuringCharges	1700000	USD
	us-gaap	Restructuring Charges RestructuringCharges	1669526	USD
	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	0	USD
	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	485000	USD
CY2017Q3	us-gaap	Restructuring Reserve RestructuringReserve	400000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-148115202	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-170470696	USD
CY2016Q3	us-gaap	Royalty Revenue RoyaltyRevenue	47236	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	207869	USD
CY2017Q3	us-gaap	Royalty Revenue RoyaltyRevenue	58779	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	169415	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	89114	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	313000	USD
CY2017Q3	us-gaap	Sales Revenue Net SalesRevenueNet	123329	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	320378	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	645775	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	5416168	USD
CY2016Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2940862	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	9127450	USD
CY2017Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	419927	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2442931	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5942392	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3117364	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	3378243	USD
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	23978022	USD
CY2017Q3	us-gaap	Short Term Investments ShortTermInvestments	0	USD
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	745392	shares
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	19768139	USD
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	3944872	USD
CY2016Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	88208	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	674834	USD
CY2017Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	1528669	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	2012747	USD
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30339774	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30136572	shares
CY2017Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36465672	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32826306	shares
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30339774	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30018841	shares
CY2017Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36465672	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32826306	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-17-011252-index-headers.html	Edgar Link	pending
0001628280-17-011252-index.html	Edgar Link	pending
0001628280-17-011252.txt	Edgar Link	pending
0001628280-17-011252-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
trov-093017exhibit311.htm	Edgar Link	pending
trov-093017exhibit321.htm	Edgar Link	pending
trov-093017exhibit41.htm	Edgar Link	pending
trov-093017x10q.htm	Edgar Link	pending
trov-20170930.xml	Edgar Link	completed
trov-20170930.xsd	Edgar Link	pending
trov-20170930_cal.xml	Edgar Link	unprocessable
trov-20170930_def.xml	Edgar Link	unprocessable
trov-20170930_lab.xml	Edgar Link	unprocessable
trov-20170930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRDF
Cardiff Oncology, Inc. Stock $crdf

2017 Q3 Form 10-Q Financial Statement

#000162828017011252 Filed on November 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF Cardiff Oncology, Inc. Stock $crdf

2017 Q3 Form 10-Q Financial Statement

#000162828017011252 Filed on November 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF
Cardiff Oncology, Inc. Stock $crdf